Carrier-mediated or specialized transport of drugs across the blood–brain barrier
Abstract
In the drug development process, it remains a difficult task to regulate the entry of the drugs. However, recent progress in studies of the transporter-mediated influx and efflux of endogenous and exogenous compounds, including synthetic drugs, across the blood-brain barrier (BBB) is beginning to provide a rational basis for controlling drug distribution to the brain. This paper describes mechanisms established in the last decade for carrier-mediated influx and efflux of drugs and endocytosis of biologically active peptides across the BBB. The transport systems at the BBB described here are the uptake transporters for nutrients, such as amino acids and hexoses, monocarboxylates, amines, carnitine and glutathione and efflux transporters, such as P-glycoprotein and multiple organic anion transporters. Delivery of cationized peptides across the BBB via adsorptive-mediated endocytosis is also described. By utilizing such highly specific transport mechanisms, it should be possible to establish strategies to regulate the entry of candidate drugs, including peptides, into the brain.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Passive transcytosis across the blood-brain barrier permits only hydrophilic compounds with a mass lower than 150 Da and highly hydrophobic compounds with a mass lower than 400-600 Da.
“The tightness of the BBB precludes the entrance of most pharmaceuticals into the brain via passive transcytosis, except for hydrophilic compounds which have a mass lower than 150 Da and highly hydrophobic compounds which have a mass lower than 400–600 Da.157,158”
From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [157]
Cited by
Sorted by citations
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · see citing works
“The tightness of the BBB precludes the entrance of most pharmaceuticals into the brain via passive transcytosis, except for hydrophilic compounds which have a mass lower than 150 Da and highly hydrophobic compounds which have a mass lower than 400 – 600 Da.”
BackgroundA. Bartz, J., & Hollander, E. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2006.06.018 · Cited by 311 · see citing works
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152 · see citing works
Zhao, Y., Haney, M. J., Fallon, J. K., Rodriguez, M., Swain, C. J., Arzt, C. J., Smith, P. C., Loop, M. S., Harrison, E. B., El-Hage, N., et al. (2022) · Cells · doi:10.3390/cells11121933 · Cited by 39 · see citing works
- Authors
- Tsuji, A., & Tamai, I.
- Affiliations
- Kanazawa University (JP)
- Corresponding author
- Tsuji, Akira
- ORCID
- Tamai, Ikumi
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 36
- Issue
- 2-3
- Pages
- 277-290
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1992983740
- Cited by
- 174
- References
- 0
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 5 · 2012: 2
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- blood-brain barrier, drug transport, carrier-mediated transport, efflux pumps, P-glycoprotein, organic anion transporters, amino acid transporters, hexose transporters, monocarboxylate transporters, carnitine transport, glutathione transport, endocytosis, brain drug delivery, brain drug distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review